There are three things that create drag on investment returns: 1) Losses 2) Taxes 3) Fees We spend most of our time trying to reduce losses and increase gains, but we spend little time and attention on the second two items. This is short-sighted given the fact that both taxes and fees are much more… Continue reading Tax Strategies – QSBS
We had several financings that didnt make the 12/1 edition of Vital Signs. Biolexis Therapeutics – a company using AI for metabolic drug discovery, raised a $10M Series A. (American Fork, UT) Aperiam Bio – a protein engineering company, raised a $9M Seed extension.(Brooklyn, NY) Arrivo Bioventures – a drug developer, raised a $45M Series… Continue reading Financings – Cont. from Vital Signs 12/1/23
When a startup or an investment is successful, it’s more likely that we attribute the outcome to a great idea and solid execution. While these two attributes are critical, they are not sufficient. skill. Over the years, some of our most successful entrepreneurs and investors have shared that luck is underestimated in this equation. Mark… Continue reading Luck
We had several financings that didnt make the 11/14 edition of Vital Signs. VectorY Therapeutics – a biotech company developing antibody therapies to treat neurodegenerative diseases, raised a $138M Series A. (Amsterdam, Netherlands) Needed – a company that develops nutrition products for prenatal care, raised $14M. (LA, CA)
Listings that didn’t get included in the 11/7/23 edition of Vital Signs are here. If you are NOT receiving Vital Signs via email, send us a note and we’ll make sure to get you on the distribution list. The email briefing is designed to keep you informed of financings, new ideas and provide helpful educational… Continue reading Financings – Cont. from Vital Signs 11/7/23
The slow medtech IPO (Initial Public Offering) market in 2023 is having a significant impact on venture capital investments in the medical technology (medtech) sector. For purposes of this post, we include therapeutics and digital health in the broad term “medtech.” According to Evaluate Medtech, there were exactly zero IPOs in the space in the… Continue reading The MedTech IPO Market is Dead
Listings that didn’t get included in the 9/29/23 edition of Vital Signs are here. If you are NOT receiving Vital Signs via email, send us a note and we’ll make sure to get you on the distribution list. The email briefing is designed to keep you informed of financings, new ideas and provide helpful educational… Continue reading Financings – Continued from Vital Signs 9/29/23
Medtech financings continue at a rapid pace led by therapeutics, AI and robotics. Below are just a few of the fundings we couldnt fit into a Vital Signs newsletter. CMR Surgical – a surgical robotics company, raised $165M. (Cambridge, UK) Corti – an AI assistant for healthcare professionals, raised a $60M Series B. (Copenhagen, DN)… Continue reading Medtech Financings
Mark Sanborn is a leading author and speaker with deep expertise on the topics of leadership and teams. His most recent post shares 10 mistakes leaders make in their thinking. None of the 10 will surprise you, but it’s a useful list and refresher for all leaders. We all have blind-spots, and the most effective… Continue reading 10 Common Thinking Errors Leaders Make
While animal health is not at the top of the news cycle in healthcare, it continues to be a space that attracts considerable PE attention and money. On the one hand there is the fact that “translational medicine” has increasingly become mainstream in the last decade and the dollars being spent on animal health continue… Continue reading M&A in the Vet Space Continues
AngelMD is a large and growing healthcare innovation community connecting clinicians, startups, investors, Industry and other stakeholders.
AngelMD is a large and growing healthcare innovation community centered around clinician & startups with tools & education for both.
